Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30,372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.
Jalota-Badhwar A, Bhatia DR, Boreddy S, Joshi A, Venkatraman M, Desai N, Chaudhari S, Bose J, Kolla LS, Deore V, Yewalkar N, Kumar S, Sharma R, Damre A, More A, Sharma S, Agarwal VR. Jalota-Badhwar A, et al. Among authors: kumar s. Mol Cancer Ther. 2015 May;14(5):1095-106. doi: 10.1158/1535-7163.MCT-14-0486. Epub 2015 Feb 19. Mol Cancer Ther. 2015. PMID: 25700704
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Venkatesha VA, Joshi A, Venkataraman M, Sonawane V, Bhatia D, Tannu P, Bose J, Choudhari S, Srivastava A, Pandey PK, Lad VJ, Sangana R, Ahmed T, Damre A, Deore V, Sahu B, Kumar S, Sharma S, Agarwal VR. Venkatesha VA, et al. Among authors: kumar s. Mol Cancer. 2014 Dec 2;13:259. doi: 10.1186/1476-4598-13-259. Mol Cancer. 2014. PMID: 25466244 Free PMC article.
Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors.
Deore V, Yewalkar N, Bhatia D, Desai N, Gupte RD, Dadarkar SS, Jadhav MG, Tannu AA, Bhatt P, Nemmani KV, Vishwakarma RA, Sharma S, Roychowdhury A, Dagia NM, Bhonde MR, Kumar S. Deore V, et al. Among authors: kumar s. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2949-52. doi: 10.1016/j.bmcl.2009.04.055. Epub 2009 Apr 18. Bioorg Med Chem Lett. 2009. PMID: 19409777
Development of novel inhibitors targeting HIF-1α towards anticancer drug discovery.
Yewalkar N, Deore V, Padgaonkar A, Manohar S, Sahu B, Kumar P, Jalota-Badhwar A, Joshi KS, Sharma S, Kumar S. Yewalkar N, et al. Among authors: kumar s, kumar p. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6426-9. doi: 10.1016/j.bmcl.2010.09.083. Epub 2010 Sep 18. Bioorg Med Chem Lett. 2010. PMID: 20932758
The therapeutic potential of GPR120: a patent review.
Halder S, Kumar S, Sharma R. Halder S, et al. Among authors: kumar s. Expert Opin Ther Pat. 2013 Dec;23(12):1581-90. doi: 10.1517/13543776.2013.842977. Epub 2013 Oct 6. Expert Opin Ther Pat. 2013. PMID: 24094095 Review.
30,372 results
You have reached the last available page of results. Please see the User Guide for more information.